Dysregulation of the RANKL/RANK/OPG Axis in Thalassemia Intermedia Patients

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2018 Aug 2

PMID 30064480

Citations 4

Authors

Mahmoud A Alfaqih

Nabil Bashir

Rami Saadeh

Yousef Khader

Musa Barqawi

Sara Alqudah

Affiliations

Soon will be listed here.

Abstract

Objective: Thalassemia intermedia (TI) describes a disease ranging in severity between β thalassemia major (TM) and β thalassemia trait. Osteoporosis is observed in TI and TM. The exact reason of osteoporosis in TI could be hypogonadism and/or an increase in erythropoietin (EPO) levels. The carboxy-terminal collagen cross links (CTX), a marker of bone resorption, and the N-terminal propeptide of type 1 collagen (P1NP), a marker of bone formation are serum markers of osteoporosis. The receptor activator of NF-kappaB ligand (RANKL)/receptor activator of NF-kappaB (RANK)/osteoprotegerin (OPG) axis plays an important role in metabolic bone diseases. Herein, we tested the relationship between the RANKL/RANK/OPG axis and the bone-turnover markers CTX and P1NP in TI.

Results: We recruited 44 TI patients and 33 non-thalassemic controls and measured the serum levels of hemoglobin, sex steroid hormones, CTX, P1NP, RANKL and OPG. We then used a general linear model to test the association of the above variables with CTX and P1NP as outcome variables. We showed that EPO levels were the strongest predictor of CTX change (P < 0.000), followed by RANKL (P = 0.017). On the other hand, RANKL was the strongest predictor of P1NP change (P < 0.000), followed by OPG (P = 0.009) and EPO (P = 0.024).

Citing Articles

New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.

Carsote M, Vasiliu C, Trandafir A, Albu S, Dumitrascu M, Popa A Diagnostics (Basel). 2022; 12(8).

PMID: 36010271 PMC: 9406368. DOI: 10.3390/diagnostics12081921.

Assessment of biochemical bone markers of osteoporosis in children with thalassemia major.

Celik T, Sangun O, Unal S, Balci A, Motor S Ital J Pediatr. 2022; 48(1):105.

PMID: 35725492 PMC: 9210807. DOI: 10.1186/s13052-022-01290-x.

Effect of vitamin D supplementation on OPG/RANKL signalling activities in endothelial tissue damage in diet-induced diabetic rat model.

Celebi G, Anapali M, Dagistanli F, Akdemir A, Aydemir D, Ulusu N Pharmacol Rep. 2021; 74(1):124-134.

PMID: 34657267 DOI: 10.1007/s43440-021-00332-1.

Icariin Prevents Diabetes-Induced Bone Loss in Rats by Reducing Blood Glucose and Suppressing Bone Turnover.

Qi S, He J, Zheng H, Chen C, Lan S Molecules. 2019; 24(10).

PMID: 31096652 PMC: 6571757. DOI: 10.3390/molecules24101871.

References

Wright H, McCarthy H, Middleton J, Marshall M . RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med. 2009; 2(1):56-64. PMC: 2684955. DOI: 10.1007/s12178-009-9046-7. View

Saki N, Abroun S, Salari F, Rahim F, Shahjahani M, Javad M . Molecular Aspects of Bone Resorption in β-Thalassemia Major. Cell J. 2015; 17(2):193-200. PMC: 4503833. DOI: 10.22074/cellj.2016.3713. View

Noetzli L, Panigrahy A, Mittelman S, Hyderi A, Dongelyan A, Coates T . Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol. 2012; 87(2):167-71. DOI: 10.1002/ajh.22247. View

Taher A, Musallam K, Cappellini M, Weatherall D . Optimal management of β thalassaemia intermedia. Br J Haematol. 2011; 152(5):512-23. DOI: 10.1111/j.1365-2141.2010.08486.x. View

Wada T, Nakashima T, Hiroshi N, Penninger J . RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2005; 12(1):17-25. DOI: 10.1016/j.molmed.2005.11.007. View

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

Bachrach L . Dual energy X-ray absorptiometry (DEXA) measurements of bone density and body composition: promise and pitfalls. J Pediatr Endocrinol Metab. 2000; 13 Suppl 2:983-8. View

Haidar R, Musallam K, Taher A . Bone disease and skeletal complications in patients with β thalassemia major. Bone. 2010; 48(3):425-32. DOI: 10.1016/j.bone.2010.10.173. View

Terpos E, Voskaridou E . Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci. 2010; 1202:237-43. DOI: 10.1111/j.1749-6632.2010.05542.x. View

10.

Galanello R, Cao A . Relationship between genotype and phenotype. Thalassemia intermedia. Ann N Y Acad Sci. 1998; 850:325-33. DOI: 10.1111/j.1749-6632.1998.tb10489.x. View

11.

Hofbauer L, Khosla S, Dunstan C, Lacey D, Spelsberg T, Riggs B . Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999; 140(9):4367-70. DOI: 10.1210/endo.140.9.7131. View

12.

Hosking D, Chilvers C, Christiansen C, Ravn P, Wasnich R, Ross P . Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med. 1998; 338(8):485-92. DOI: 10.1056/NEJM199802193380801. View

13.

Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo M, Cincotta M . Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res. 2004; 19(5):722-7. DOI: 10.1359/JBMR.040113. View

14.

Sturgeon P, ITANO H, BERGREN W . Genetic and biochemical studies of intermediate types of Cooley's anaemia. Br J Haematol. 1955; 1(3):264-77. DOI: 10.1111/j.1365-2141.1955.tb05509.x. View

15.

Aubin J, Bonnelye E . Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 2001; 11(11):905-13. DOI: 10.1007/s001980070028. View

16.

Boyce B, Xing L . The RANKL/RANK/OPG pathway. Curr Osteoporos Rep. 2007; 5(3):98-104. DOI: 10.1007/s11914-007-0024-y. View

17.

Perisano C, Marzetti E, Spinelli M, Calla C, Graci C, Maccauro G . Physiopathology of Bone Modifications in β-Thalassemia. Anemia. 2012; 2012:320737. PMC: 3369393. DOI: 10.1155/2012/320737. View

18.

Musallam K, Taher A, Rachmilewitz E . β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med. 2012; 2(7):a013482. PMC: 3385943. DOI: 10.1101/cshperspect.a013482. View

19.

Emerit J, Beaumont C, Trivin F . Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother. 2001; 55(6):333-9. DOI: 10.1016/s0753-3322(01)00068-3. View

20.

Camaschella C, Cappellini M . Thalassemia intermedia. Haematologica. 1995; 80(1):58-68. View